In general, PDL1 expression is an effective marker of response to ICI therapy in some tumors, such as non-small cell lung cancer and urothelial carcinoma (55, 56), but is not a good predictor of ICI response in CRC (57). The gene discussed is CD274; the disease is non-small cell lung carcinoma.